<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769418</url>
  </required_header>
  <id_info>
    <org_study_id>0822-002</org_study_id>
    <secondary_id>MK0822-002</secondary_id>
    <secondary_id>2008_558</secondary_id>
    <nct_id>NCT00769418</nct_id>
  </id_info>
  <brief_title>Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Multiple Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0822 in Healthy Male and Postmenopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      once-daily multiple-dose administration of odanacatib (MK0822).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of MK0822</measure>
    <time_frame>After 14 days of treatment for men and 21 days for women</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of MK0822</measure>
    <time_frame>predose and at selected time intervals postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>odanacatib (MK0822)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to odanacatib (MK0822)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>odanacatib</intervention_name>
    <description>Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: odanacatib tablets 2.5 mg qd for 14 days.
Panel B: odanacatib tablets 5 mg qd for 14 days.
Panel C: odanacatib tablets 10 mg qd for 14 days.
Panel D: odanacatib tablets 25 mg qd for 14 days.
Panel E: odanacatib tablets 0.5 mg qd for 21 days.
Panel F: odanacatib tablets 2.5 mg qd for 21 days.
Panel G: odanacatib tablets 10 mg qd for 21 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0822</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.
Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.
Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.
Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.
Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.
Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.
Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male between the ages of 18 and 45 or a female less than or equal to 70
             years of age

          -  Females must be past menopause

          -  Subject is a nonsmoker

          -  Subject is willing to avoid excessive alcohol consumption during the study and is
             willing to avoid alcohol entirely for 24 hours prior to drug administration and during
             PK sampling

          -  Subject is willing to refrain from consuming grapefruit or grapefruit juice

        Exclusion Criteria:

          -  Subject has a history of multiple/severe allergies to drugs or food

          -  Subject has donated blood within 4 weeks of starting the study

          -  Subject has a history of metabolic bone disease, urolithiasis, or bisphosphonate
             treatment

          -  Subject has any infections or any condition leading to immune problems, including HIV

          -  Subject regularly uses illegal drugs

          -  Subject consumes more than 3 alcoholic beverages per day

          -  Subject drinks 4 or more caffeinated beverages per day

          -  Subject uses any prescription or nonprescription medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009 Aug;86(2):175-82. doi: 10.1038/clpt.2009.60. Epub 2009 May 6.</citation>
    <PMID>19421185</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

